Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
acetylcholine receptor
acetylcholine receptor antibody
autoimmune disease
immunologic disease
immunosuppressive agents
Mary Walker phenomenon
myasthenia gravis
myasthenia gravis, neonatal
myasthenia gravis, neuromuscular junction in
myasthenia gravis, passive transfer of
myasthenia gravis, receptor site in
myasthenia gravis, thymectomy in
myasthenia gravis, treatment of
plasmapheresis
steroid therapy, CNS treatment and complications with
thymus and neuromuscular function
Showing articles 0 to 50 of 509 Next >>

Myasthenia Gravis
NEJM 298:136, Drachman,D.B., 1978

Myasthenia Gravis, Study of Humoral Immune Mechanisms by Passive Transfer to Mice
NEJM 296:125, Toyka,K.V.,et al, 1977

Addressing Systemic Complications of Acute Stroke: A Scientific Statement From the American Heart Association
Stroke 56:e15-e29, Kumar,S.,et al, 2025

Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice
Neurol 104:e213498, Zara,P.,et al, 2025

The "Chameleon Eyes Sign" in Myasthenia Gravis
Neurol 103:e209756, Zara,P.,et al, 2024

Clinicopathologic Conference, Myasthenia Gravis
NEJM 391:1441-1450, Case 32-2024, 2024

Clinicopathologic Conference, Brain Abscess Due to Infection with Listeria Monocytogeneses
NEJM 391:1529-1538, Case 33-2024, 2024

Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology
Ann Neurol 96:1020-1025, Falso,S.,et al, 2024

Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024

Ocular Myasthenia Gravis, Central Ocular Motor Signs and Unilateral Visual Loss Caused by the Great Neuro-Ophthalmologic Impersonator
Neurol 102:e209260, Young,A. & Johnston,J.L., 2024

Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis
Neurol 98:e2368-e2376, Molimard, A.,et al, 2022

A New Option is Approved for Patients with Myasthenia Gravis
JAMA 327:417, Voelker, R., 2022

Curtain Sign
NEJM 387:e7, Sherman, S.V., 2022

A 71-Year-Old Man Presenting with Acute Onset Dysarthria and Dysphagia
Neurol 96:180-184, Spagni, G.,et al, 2021

A 68-Year-Old Man with Proximal Weakness and Seizures
Neurol 97:e423-e428, Chen, T., 2021

Myasthenia Grais
www.mda.org, , 2021

Acetylcholine Receptor-Antibody-Positive Myasthenia Gravis Presenting with Early Atrophy and Nonfluctuating Weakness of Proximal Limb Muscles
J Clin Neurol 16:714-716, Pancheri, E.,et al, 2020

Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020

Myasthenic Crisis Demanding Mechanical Ventilation
Neurol 94:e299-e313, Neumann, B.,et al, 2020

Long-Term Follow-Up, Quality of Life, and Survival of Patients with Lambert-Eaton Myasthenic Syndrome
Neurol 94:e511-e520, Lipka, A.F.,et al, 2020

Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020

Useful Bedside Testing for Myasthenia Gravis
Neurol 94:e1870-e1871, Gomes del Carvalho Neto, E.,et al, 2020

Thymectomy for Myasthenia Gravis
Neurol 94:705-709, Gronseth, G.S.,et al, 2020

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

The Face of Myasthenia Gravis
Neurol 95:89-90, Ruiter, A.M.,et al, 2020

Ptosis that Resolves with Application of an Ice Pack
BMJ 369:m1147, Chakraborty, A. & Jacob, J., 2020

Drug Approved for Rare Muscle Weakening Syndrome
JAMA 321:239, Voelker, R., 2019

Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019

Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis
Muscle Nerve 60:14-24, Muppidi, S.,et al, 2019

Bilateral Cavernous Carotid Aneurysms: Atypical Presentation of a Rare Cause of Mass Effect
Front Neurol doi:10.3389/fneur.2018.0069, Gagliardi, D.,et al, 2018

Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018

A Child with Arthrogryposis
Neurol 91:e995-e998, Irumudomom, O. & Ghosh, P.S., 2018

Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018

Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018

Congenital Myasthenic Syndromes in Adult Neurology Clinic
Neurol 91:e1770-e1777, Kao, J.C.,et al, 2018

A Child with Delayed Motor Milestones and Ptosis
Neurol 88:e158-e163, Ghosh, P.S., 2017

Dont Fall for Pseudo-INO
Neurol 88:e205-e206, Traber, G.L.et al, 2017

Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017

Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis
JAMA Neurol 74:60-66, Robeson, K.R.,et al, 2017

Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016

Mechanisms, Causes, and Effects of Hypercapnia
UptoDate Dec, Feller-Kopman, D.J. & Schwartzstein, R.M., 2016

Myasthenia Gravis Exacerbation after Discontinuing Mycophenolate
Neurol 86:1159-1163, Oskarsson, B.,et al, 2016

Myasthenia Gravis Treated with Autologous Hematopoietic Stem Cell Transplantation
JAMA Neurol 73:652-658,624, Bryant, A.,et al, 2016

A Randomized Controlled Trial of Methotrexate for Patients with Generalized Myasthenia Gravis
Neurol 87:57-64, Pasnoor, M.,et al, 2016

International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016

Randomized Trial of Thymectomy in Myasthenia Gravis
NEJM 375:511-522,576, Wolfe, G.I.,et al, 2016

Clinical Manifestations of Myasthenia Gravis
UptoDate Aug 2016, Bird, S.J., 2016

Myasthenia Gravis after Botulinum Toxin Type A Injection
Turk J Neurol 22:143-144, Tekce, H.D.,et al, 2016



Showing articles 0 to 50 of 509 Next >>